Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.064 AUD | +4.92% | +6.67% | -9.86% |
Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Valuation
Fiscal Period: Junio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 74.36 | 58.24 | 35.18 | 185.9 | 56.99 | 12.57 |
Enterprise Value (EV) 1 | 65.03 | 59.26 | 33.08 | 159.5 | 43.14 | 9.558 |
P/E ratio | -3.51 x | -5.16 x | -82.5 x | -18.2 x | -3.04 x | -0.83 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 81.1 x | 15.5 x | 4.22 x | 33.1 x | 10.5 x | 2.09 x |
EV / Revenue | 70.9 x | 15.8 x | 3.97 x | 28.4 x | 7.95 x | 1.59 x |
EV / EBITDA | -6.83 x | -5 x | -4.2 x | -11 x | -4.53 x | -0.91 x |
EV / FCF | 22.7 x | -12.7 x | -3.12 x | -32.2 x | -4.23 x | -1.37 x |
FCF Yield | 4.4% | -7.86% | -32.1% | -3.11% | -23.6% | -73.2% |
Price to Book | 7.33 x | -579 x | 2.73 x | 4.56 x | 2.36 x | 1.38 x |
Nbr of stocks (in thousands) | 121,901 | 122,601 | 213,201 | 288,222 | 292,238 | 292,238 |
Reference price 2 | 0.6100 | 0.4750 | 0.1650 | 0.6450 | 0.1950 | 0.0430 |
Announcement Date | 8/30/18 | 8/29/19 | 8/31/20 | 8/26/21 | 8/25/22 | 8/31/23 |
Income Statement Evolution (Annual data)
Fiscal Period: Junio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 0.9165 | 3.751 | 8.332 | 5.608 | 5.429 | 6.01 |
EBITDA 1 | -9.525 | -11.85 | -7.868 | -14.54 | -9.518 | -10.49 |
EBIT 1 | -9.584 | -11.91 | -8.034 | -14.59 | -9.779 | -10.64 |
Operating Margin | -1,045.69% | -317.63% | -96.42% | -260.22% | -180.14% | -177.12% |
Earnings before Tax (EBT) 1 | -18.32 | -12.57 | -0.9996 | -9.347 | -18.67 | -15.06 |
Net income 1 | -18.28 | -11.22 | -0.2721 | -9.347 | -18.67 | -15.06 |
Net margin | -1,994.85% | -299.22% | -3.27% | -166.66% | -343.86% | -250.52% |
EPS 2 | -0.1739 | -0.0920 | -0.002000 | -0.0354 | -0.0641 | -0.0515 |
Free Cash Flow 1 | 2.864 | -4.658 | -10.61 | -4.956 | -10.19 | -6.998 |
FCF margin | 312.52% | -124.18% | -127.35% | -88.37% | -187.8% | -116.44% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 8/30/18 | 8/29/19 | 8/31/20 | 8/26/21 | 8/25/22 | 8/31/23 |
Balance Sheet Analysis
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 1.02 | - | - | - | - |
Net Cash position 1 | 9.33 | - | 2.1 | 26.4 | 13.9 | 3.01 |
Leverage (Debt/EBITDA) | - | -0.0861 x | - | - | - | - |
Free Cash Flow 1 | 2.86 | -4.66 | -10.6 | -4.96 | -10.2 | -7 |
ROE (net income / shareholders' equity) | -290% | -289% | -17.5% | -34.8% | -57.5% | -90.7% |
ROA (Net income/ Total Assets) | -68.9% | -79% | -41.2% | -26.9% | -16.4% | -36.2% |
Assets 1 | 26.52 | 14.21 | 0.6602 | 34.8 | 113.7 | 41.55 |
Book Value Per Share 2 | 0.0800 | -0 | 0.0600 | 0.1400 | 0.0800 | 0.0300 |
Cash Flow per Share 2 | 0.1000 | 0.0200 | 0.0300 | 0.0900 | 0.0500 | 0.0100 |
Capex 1 | 0.31 | 0.01 | 0 | - | - | - |
Capex / Sales | 34.08% | 0.17% | 0.04% | - | - | - |
Announcement Date | 8/30/18 | 8/29/19 | 8/31/20 | 8/26/21 | 8/25/22 | 8/31/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-9.86% | 12.2M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- NOX Stock
- Financials Noxopharm Limited